The FDA on November 13, 2013 granted accelerated approval to IMBRUVICA ® for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. IMBRUVICA ® is an oral capsule and is a product of Pharmacyclics, Inc.
Bottom Ad
Advertisement
Subscribe
